All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Investigators at the ECOG-ACRIN Cancer Research Group and the National Cancer Institute reported a roughly 40% match rate of patients to molecularly targeted therapies in its NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial, ultimately leading to molecularly targeted treatments for almost 20% of trial participants.